Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jan;29(1):e13229.
doi: 10.1111/srt.13229. Epub 2022 Nov 3.

Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta-analysis

Haoran Zhang  1 , Ai Zhong  1 , Junjie Chen  1
Affiliations
Meta-Analysis

Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta-analysis

Haoran Zhang et al. Skin Res Technol. 2023 Jan.

Abstract

Background: To evaluate the immune checkpoint inhibitors (CPI) for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC).

Materials and methods: A meta-analysis was conducted, and the efficacy and safety of CPI were assessed.

Results: A total of 13 studies with 980 patients were included. The pooled objective response rate (ORR) and disease control rate were 47.2% and 64.4%, separately. In addition, patients with primary tumor located in head and neck (odds ratio [OR]: 0.374, 95% confidence interval [CI]: 0.219-0.640, p < 0.001) and positive expression of programmed death ligand 1 (OR: 0.364, 95% CI: 0.158-0.842, P = 0.018) had superior ORR during CPI treatment. The incidence of progression free survival at 6 and 12 months was 59.3% and 52.8%, and 80.6% and 76.4% for overall survival. As for safety, the overall incidence of adverse events with all grades and 3-4 grade was 76.9% and 20.2%.

Conclusions: Our systematic review confirmed the satisfying efficacy and acceptable toxicity of CPI for advanced CSCC.

Keywords: cemiplimab; cutaneous squamous cell carcinoma; immune checkpoint inhibitors; meta-analysis; nivolumab; pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

FIGURE 1
FIGURE 1
Flowchart of the selection process of eligible studies
FIGURE 2
FIGURE 2
Association between clinicopathological and molecular features of patients and ORR. (A) primary tumor locations; (B) PD‐L1 expression status; (C) immune status
See this image and copyright information in PMC

References

    1. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. AMA Dermatol. 2015;151(10):1081‐1086. - PubMed
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7‐33. - PubMed
    1. Leiter U, Keim U, Eigentler T, et al. Incidence, mortality, and trends of nonmelanoma skin cancer in Germany. J Invest Dermatol. 2017;137(9):1860‐1867. - PubMed
    1. Kauvar ANB, Arpey CJ, Hruza G, Olbricht SM, Bennett R, Mahmoud BH. Consensus for nonmelanoma skin cancer treatment, part II: squamous cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg. 2015;41(11):1214‐1240. - PubMed
    1. Brunner M, Veness Michael J, Ch'ng S, Elliott M, Clark JR. Distant metastases from cutaneous squamous cell carcinoma–analysis of AJCC stage IV. Head Neck. 2013;35(1):72‐75. - PubMed

MeSH terms

Substances